{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:05:20Z","timestamp":1769605520376,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Global Antibiotic Research and Development Partnership"},{"name":"Reoxcyn, Inc."},{"name":"Yaso Therapeutics"},{"name":"Microbiotix, Inc."},{"name":"Venatorx, Inc"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Siena"},{"name":"Debiopharm"},{"name":"Merlion Pharmaceuticals"},{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eumedica"},{"name":"Shionigi Inc."}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.cmi.2020.08.006","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T11:55:19Z","timestamp":1597319719000},"page":"1630-1635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetic\/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea\u2014challenges and opportunities"],"prefix":"10.1016","volume":"26","author":[{"given":"Ursula","family":"Theuretzbacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindley","family":"Barbee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristie","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabha","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Hook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"VanScoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Warn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Alirol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.08.006_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.cmi.2020.08.006_bib2","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1016\/j.vaccine.2018.02.081","article-title":"Biological feasibility and importance of a gonorrhea vaccine for global public health","volume":"37","author":"Vincent","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2020.08.006_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"Unemo","year":"2019","journal-title":"Gonorrhoea Nat Rev Dis Primers"},{"key":"10.1016\/j.cmi.2020.08.006_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.cmi.2020.08.006_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/antibiotics7020049","article-title":"Future prospects for Neisseria gonorrhoeae treatment","volume":"7","author":"Suay-Garc\u00eda","year":"2018","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2020.08.006_bib6","article-title":"Using genomics to understand antimicrobial resistance and transmission in Neisseria gonorrhoeae","volume":"5","author":"S\u00e1nchez-Bus\u00f3","year":"2019","journal-title":"Microb Genom"},{"key":"10.1016\/j.cmi.2020.08.006_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002366","article-title":"Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines","volume":"14","author":"Alirol","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2020.08.006_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Inf Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1473-3099(19)30430-X","article-title":"Phase 3 trial of treating gonorrhoea with solithromycin","volume":"19","author":"Fernandes","year":"2019","journal-title":"Lancet Inf Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, non-inferiority, Phase 3, multicenter, randomized study","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","article-title":"Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Inf Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib15","author":"WHO"},{"key":"10.1016\/j.cmi.2020.08.006_bib16","author":"FDA"},{"key":"10.1016\/j.cmi.2020.08.006_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/OLQ.0000000000000994","article-title":"Standards for treatment and control regimens in therapeutic trials for gonorrhea: lessons from a \u201cfailed\u201d trial","volume":"46","author":"Handsfield","year":"2019","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/CMR.17.4.965-981.2004","article-title":"The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women","volume":"17","author":"Edwards","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2020.08.006_bib20","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/iai.65.6.2420-2427.1997","article-title":"Ultrastructural analysis of primary human urethral epithelial cell cultures infected with Neisseria gonorrhoeae","volume":"65","author":"Harvey","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2020.08.006_bib21","first-page":"133","article-title":"A\u00a0subpopulation of intracellular Neisseria gonorrhoeae escapes autophagy-mediated killing inside epithelial cells","volume":"219","author":"Lu","year":"2018","journal-title":"J\u00a0Inf Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development","volume":"71","author":"Rice","year":"2017","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib23","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.tim.2018.07.003","article-title":"Gonococcal defenses against antimicrobial activities of neutrophils","volume":"26","author":"Palmer","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib24","first-page":"353","article-title":"Penetration of penicillin into human phagocytes containing Neisseria gonorrhoeae: intracellular survival and growth at optimum concentrations of antibiotic","volume":"95","author":"Veale","year":"1976","journal-title":"Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/cmi.12117","article-title":"Neisseria gonorrhoeae phagosomes delay fusion with primary granules to enhance bacterial survival inside human neutrophils","volume":"15","author":"Johnson","year":"2013","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fmicb.2011.00077","article-title":"Resistance of Neisseria gonorrhoeae to neutrophils","volume":"2","author":"Johnson","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro.2017.169","article-title":"Neisseria gonorrhoeae host adaptation and pathogenesis","volume":"16","author":"Quillin","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4269\/ajtmh.19-0288","article-title":"Characteristics and impact of disseminated gonococcal infection in the \u201cTop End\u201d of Australia","volume":"101","author":"Birrell","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2020.08.006_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0891-5520(03)00060-6","article-title":"Antimicrobial tissue concentrations","volume":"17","author":"Liu","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2020.08.006_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jac\/dkg223","article-title":"Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus","volume":"51","author":"Seral","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib31","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib33","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.3390\/antibiotics8020054","article-title":"Intracellular penetration and effects of antibiotics on Staphylococcus aureus inside human neutrophils: a comprehensive review","volume":"8","author":"Bongers","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2020.08.006_bib34","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.micinf.2008.06.014","article-title":"Quantification of bacterial internalization by host cells using a beta-lactamase reporter strain: Neisseria gonorrhoeae invasion into cervical epithelial cells requires bacterial viability","volume":"10","author":"Bish","year":"2008","journal-title":"Microbe. Infect"},{"key":"10.1016\/j.cmi.2020.08.006_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40262-017-0572-y","article-title":"Intracellular pharmacokinetics of antibacterials and their clinical implications","volume":"57","author":"Pea","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2020.08.006_bib36","first-page":"218","article-title":"Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives","volume":"9","author":"Van Bambeke","year":"2006","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.cmi.2020.08.006_bib37","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/AAC.49.6.2372-2377.2005","article-title":"Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin","volume":"49","author":"Bosnar","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1248\/bpb.b13-00423","article-title":"Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in\u00a0vitro","volume":"36","author":"Togami","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.cmi.2020.08.006_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-4939-2854-5_13","article-title":"In\u00a0vitro models for the study of the intracellular activity of antibiotics","volume":"1333","author":"Buyck","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cmi.2020.08.006_bib40","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1128\/AAC.50.5.1689-1695.2006","article-title":"Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages","volume":"50","author":"Michot","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","volume":"17","author":"Carryn","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2020.08.006_bib42","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jac\/dky548","article-title":"Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review","volume":"74","author":"Kong","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib44","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.08.006_bib45","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial","volume":"393","author":"Ross","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.08.006_bib46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/QCO.0000000000000058","article-title":"Preparing for an era of untreatable gonorrhea","volume":"27","author":"Barbee","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02069-17","article-title":"Neisseria cinerea with high ceftriaxone mic is a source of ceftriaxone and cefixime resistance-mediating penA sequences in Neisseria gonorrhoeae","volume":"62","author":"Igawa","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30306-8","article-title":"Kissing, saliva exchange, and transmission of Neisseria gonorrhoeae","volume":"19","author":"Hook","year":"2019","journal-title":"Lancet Inf Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib49","article-title":"Gentamicin alone is inadequate to eradicate Neisseria gonorrhoeae from the pharynx","author":"Barbee","year":"2019","journal-title":"Clin Inf Dis"},{"key":"10.1016\/j.cmi.2020.08.006_bib50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40262-015-0321-z","article-title":"A\u00a0qualitative review on the pharmacokinetics of antibiotics in saliva: implications on clinical pharmacokinetic monitoring in humans","volume":"55","author":"Kiang","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2020.08.006_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib52","doi-asserted-by":"crossref","first-page":"e02307","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in\u00a0vitro and in\u00a0vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2017.09.011","article-title":"Pre-clinical in\u00a0vitro infection models","volume":"36","author":"Drusano","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cmi.2020.08.006_bib54","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/jac\/dkz376","article-title":"In\u00a0vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae","volume":"74","author":"Foerster","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib55","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1038\/srep11827","article-title":"Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases","volume":"5","author":"Basarab","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2020.08.006_bib56","series-title":"A\u00a0hollow-fiber infection model to evaluate the prevention of on-therapy resistance of Neisseria gonorrhoeae to gepotidacin. STD Prevention Conference; 27\u201330 August 2018; Washington DC","year":"2018"},{"key":"10.1016\/j.cmi.2020.08.006_bib57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fmicb.2011.00102","article-title":"The pathobiology of Neisseria gonorrhoeae lower female genital tract infection","volume":"2","author":"Edwards","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2020.08.006_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008136","article-title":"Neisseria gonorrhoeae infects the heterogeneous epithelia of the human cervix using distinct mechanisms","volume":"15","author":"Yu","year":"2019","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.cmi.2020.08.006_bib59","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1128\/AAC.46.7.2095-2103.2002","article-title":"Comparative intracellular (THP-1 macrophage) and extracellular activities of \u03b2-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations","volume":"46","author":"Carryn","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib60","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1128\/AAC.00564-13","article-title":"Determination of in\u00a0vitro activities of solithromycin at different pHs and its intracellular activity against clinical isolates of Neisseria gonorrhoeae from a laboratory collection","volume":"57","author":"Mallegol","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.01049-16","article-title":"Human three-dimensional endometrial epithelial cell model to study host interactions with vaginal bacteria and Neisseria gonorrhoeae","volume":"85","author":"\u0141aniewski","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2020.08.006_bib62","series-title":"Neisseria gonorrhoeae: methods and protocols","first-page":"413","article-title":"Female mouse model of Neisseria gonorrhoeae infection","author":"Raterman","year":"2019"},{"key":"10.1016\/j.cmi.2020.08.006_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01644-18","article-title":"Pharmacokinetic data are predictive of in\u00a0vivo efficacy for cefixime and ceftriaxone against susceptible and resistant neisseria gonorrhoeae strains in the gonorrhea mouse model","volume":"63","author":"Connolly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib64","first-page":"2141","article-title":"Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?","volume":"65","author":"Chisholm","year":"2010","journal-title":"J\u00a0Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib65","first-page":"e01409","article-title":"Evaluation of the microbiological efficacy of a single 2-gram dose of extended-release azithromycin by population pharmacokinetics and simulation in Japanese patients with gonococcal urethritis","volume":"62","author":"Soda","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.08.006_bib66","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/cid\/ciz899","article-title":"Development of new antimicrobials for urogenital gonorrhea therapy: clinical trial design considerations","volume":"70","author":"Hook","year":"2020","journal-title":"Clin Inf Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20304857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20304857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:27:06Z","timestamp":1761118026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20304857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1198743X20304857"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.08.006","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea\u2014challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}